Bank of New York Mellon Corp - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 1 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q3 2022$12,000
-53.8%
49,6350.0%0.00%
Q2 2022$26,000
-89.2%
49,635
-57.4%
0.00%
Q1 2022$240,000
-50.7%
116,592
-0.2%
0.00%
Q4 2021$487,000
-38.1%
116,838
+38.0%
0.00%
Q3 2021$787,000
-39.1%
84,668
+18.0%
0.00%
Q2 2021$1,292,00071,7430.00%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 1,887,509$3,869,0003.93%
Naviter Wealth, LLC 1,571,107$3,221,0001.08%
ARMISTICE CAPITAL, LLC 5,500,000$11,275,0000.22%
INVERNESS COUNSEL LLC /NY/ 1,210,537$2,482,0000.11%
Allegheny Financial Group LTD 11,595$24,0000.01%
BALDWIN BROTHERS LLC/MA 38,604$79,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 137,700$282,0000.01%
Rafferty Asset Management, LLC 46,268$95,0000.00%
TWO SIGMA SECURITIES, LLC 15,388$32,0000.00%
Renaissance Technologies 582,392$1,194,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders